Gluten-free Bakers Have Some Time To Worry About Celiac Disease Vaccine

American biotech  company ImmusanT has developed a celiac disease vaccine that is undergoing clinical testing in New Zealand, Australia and the U.S. With the gluten-free market likely to be worth as much as US$375.5 million within a couple of years, are bakers who produce gluten-free products feeling threatened by the advancement? Not yet, they say. Availability of the novel vaccine – Nexvax2 would reduce the immune system’s adverse response to gluten – is still 10 to 15 years away.